Adenosine as an Adjunct to Blood Cardioplegia

Status Recruiting

Clinical Trial Summary

Myocardial protection is a major issue in cardiac surgery, since inadequate protection increases the risk of postoperative cardiac dysfunction. The main principle of myocardial protection in cardiac surgery is to preserve myocardial function by preventing ischemia with blood cardioplegia . Previous studies have shown that adenosine as an adjunct to blood cardioplegia can be safely used in cardiac surgery. In the Amphia Hospital, adenosine is already used as standard care as an initial cardioplegic bolus in minimally invasive port access operations. Whether, adenosine as an adjunct to intermittent warm blood cardioplegia, has an added value remains unclear. Therefore the investigators would like to investigate the effect of the addition of adenosine to standard intermittent warm blood cardioplegia in patients scheduled for minimally invasive, port access operations (mitral valve surgery).

Half of the participants will receive standard intermittent warm blood cardioplegia, while the other half will receive intermittent warm blood cardioplegia enriched with adenosine.

Clinical Trial Description

Myocardial protection is a major issue in cardiac surgery, since inadequate protection increases the risk of postoperative cardiac dysfunction. The main principle of myocardial protection in cardiac surgery is to preserve myocardial function by preventing ischemia with blood cardioplegia . Previous studies have shown that adenosine as an adjunct to blood cardioplegia can be safely used in cardiac surgery. In the Amphia Hospital, adenosine is already used as standard care as an initial cardioplegic bolus in minimally invasive port access operations. Whether, adenosine as an adjunct to intermittent warm blood cardioplegia, has an added value remains unclear. Therefore the investigators would like to investigate whether the addition of adenosine to standard intermittent warm blood cardioplegia reduces the 6-hours post-operative cardiac troponin T (cTnT) in patients scheduled for minimally invasive, port access operations (mitral valve surgery). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02681913
Study type	Interventional
Source	Amphia Hospital
Contact	Jeffrey Engelhart, PharmD
Phone	0031765954391
Email	JEngelhart@amphia.nl
Status	Recruiting
Phase	Phase 2
Start date	February 2016
Completion date	December 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05428787` - Resynchronization in Patients With HF in AF Trial Undergoing Pace & AVNA Strategy With LBBAP Compared With BiV Pacing	N/A
Not yet recruiting	`NCT05567445` - Outcome of Cardiomyopathic Adults Admission in ICU.
Completed	`NCT02555527` - Contrast Echocardiography Cost Effectiveness for Left Ventricular Thrombus Assessment	N/A
Completed	`NCT00371891` - Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)	Phase 4
Recruiting	`NCT05552521` - Diastolic Dysfunction in Septic Shock and Cardiomyopathy Genetic Variants
Recruiting	`NCT04166331` - Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion	Phase 3
Terminated	`NCT06331507` - Refinement and Assessment of New MRI Technologies for Cardiovascular Exams Using the Phillips CMR Patch	N/A
Completed	`NCT01953523` - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions	N/A
Recruiting	`NCT04695119` - Sepsis in the ICU-II
Completed	`NCT03228966` - Ped HIV - Echo Study: Kenya
Not yet recruiting	`NCT06348732` - Diagnostic and Prognostic Role of Troponin and Brain Natriuretic Peptide in Pediatric Patients With Cardiomyopathy in Correlation to Echocardiography Findings
Recruiting	`NCT05556369` - Genetic Characterization of Cardiomyopathies (POLICARDIOMIO2021)
Recruiting	`NCT04520646` - A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy	N/A
Not yet recruiting	`NCT03899298` - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions	Phase 1
Completed	`NCT04323852` - Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?	Phase 4
Completed	`NCT03527381` - Nitric Oxide in Cardiopulmonary Bypass for Renal Protection in Cardiac Surgery	Phase 1/Phase 2
Withdrawn	`NCT02462213` - Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging	N/A
Active, not recruiting	`NCT00418041` - Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)	N/A
Not yet recruiting	`NCT06091475` - Therapy to Maintain Remission in Dilated Cardiomyopathy	N/A
Recruiting	`NCT03317964` - Genetic Basis of Pacing-induced Cardiomyopathy

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.